Christopher F. Nicodemus, MD FACP, is Founder, President and Chief Scientific Officer of AIT Strategies. He served as Chairman and    Chief Scientific Officer of Advanced Immune Therapeutics, Inc., from 2008-2012. Dr. Nicodemus received undergraduate training    at Harvard College and received his MD degree Upstate Medical University in Syracuse, NY. He  trained in Internal Medicine and    completed a Research and Clinical fellowship in the laboratory of K  Frank Austen, Department of Rheumatology and Clinical Immunology    at Brigham and Women’s Hospital, Harvard Medical School, Boston. He held various research and clinical appointments at Harvard    while pursuing a career in biotechnology. He has held executive positions at Pfizer, ImmuLogic, Diatide, AltaRex, United Therapeutics    and Advanced Immune Therapeutics, Inc. He is a member of Alpha Omega Alpha and a fellow of the American College of Physicians.

His     career has been dedicated to research into immune modulation and  experimental medicine with a focus on the application of cellular    and molecular biology to clinical immunology and drug development. Early efforts using peptides as immunogens, led to the study    of T-cell reactive epitopes and tolerance induction, which subsequently evolved into study of antibodies to elicit immunity. 

An early clinical focus in allergy, autoimmunity, and asthma has more recently shifted to a focus on tumor immunology,    with an emphasis on ovarian cancer immunobiology and immunotherapy. Dr. Nicodemus has conceived, designed and executed and published    numerous clinical studies, holds multiple patents, and has extensive regulatory experience with the successful completion of    three New Drug Applications.  

Dr.  Nicodemus actively publishes and lectures in the field of translational  immunology and    Immuno-Oncology. IgE technology developed at Advanced Immune  Therapeutics, Inc. has been acquired by Quest Pharmatech, Inc. AIT    Strategies is an active participant in the continuing development of  both IgG and IgE technologies as a component of immunotherapeutic    approaches for the treatment of cancer in association with Quest  PharmaTech and partners. The recent progress in the development of    checkpoint inhibitors to unleash latent immunity in some cancer  victims has resulted in previously unachievable responses and even    cures in patients with advanced solid malignancies. The challenge for  the scientific community is now to extend this initial    success using techniques to enhance the percentage of patients able to  respond to checkpoint therapy. AIT Strategies believes that    selective and scheduled combinations utilizing this antibody  technology can achieve that objective. Working in collaboration with    Quest  PharmaTech, Shenzhen Hepalink and several associated partners,  AIT Strategies will advance these technologies in association    with the newly formed entity OncoQuest, Inc. and its Chinese joint  venture partner, OncoVent.